Virtual Symposium:
Organoid Discovery
14 April 2021 | BST (UTC+1)
Advancing understanding of organ function ex vivo to drive
innovation in drug discovery and development.

The programme brings together world leaders from international pharmaceutical organisations and leading biotechnology companies as well as globally active regulatory agencies to discuss the latest in organoid discovery. 

Download Agenda

Access the conference brochure for presentation details, topic areas and confirmed speakers for our Virtual Symposium: Organoid Discovery.

Book Online

Full Registration is now open for Virtual Symposium: Organoid Discovery. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts interested in the latest tools and strategies for organoid discovery.

Virtual Symposium: Organoid Discovery
is sponsored by our Headline Sponsor

Programme

The Virtual Symposium: Organoid Discovery includes...

Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions working within organoid discovery 

  • Spearhead discovery and emerging applications for Organ-on-a-Chip, Tissue and 3D culture platforms 
  • Propel forward understanding of how these technologies can aid drug screening, hit identification and lead optimisation strategies
  • Optimisation of target & phenotypic-based discovery
  • Gain insight into the development of 3D miniaturised assays including evaluation of targeted drug delivery and acceleration of the drug development process  

Agenda at a Glance

  • Innovative applications of Organ-on-a-Chip platforms in drug discovery: Gut-on-a-Chip, Liver-on-a-Chip, Lung-on-a-Chip, Nerve-on-a-Chip 
  • Tissue and 3D culture platforms in drug development 
  • Phenotypic and high content screening of 3D-model systems and organoids 
  • Emerging organoid models: Cancer-derived organoids 
  • Future of 3D-cell based screening methods, high content screening and data management 
  • Animal & disease modelling: Diseases-on-a-Chip, Cancer-on-a-Chip, Metastasis-on-a-Chip 
  • 3D-printing of microfluidics structures and other biologically-active structures
  • Microfluidics/Lab-on-a-Chip (LOAC) technologies for constructing Organ-on-a-Chip/Tissue-on-a-Chip/Body-on-a-Chip

Confirmed Speakers

The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future

Below were some of the speakers of 2020’s Discovery Series: Virtual

brinton seashore ludlow

Brinton Seashore Ludlow

Karolinska Institute and SciLifeLab

daniel-labarbera

Daniel Labarbera

Skaggs School Of Pharmacy And Pharmaceutical Sciences, University Of Colorado Anschutz Medical Campus

Hansjuergen Volkmer

Hansjuergen Volkmer

NMI Natural and Medical Sciences Institute at the University of Tübingen

Lutz Mueller

Lutz Mueller

F. Hoffmann-La Roche Innovation Center Basel 

Ravindra-peravali

Ravindra Peravali

Karlsruhe Institute of Technology

Sylvia Boj

Sylvia Boj

Hubrecht Organoid Technology 

Event Features​

Networking and knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences. 

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As at the end of each presentation

Digital Networking Opportunities

Connect directly with other event registrants around the world

CrownBio

Headline Sponsor

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immunology, inflammation, and metabolic disease research. Our biomarker discovery, validation, and assay services help our clients to successfully advance their preclinical and clinical therapeutic candidates.